Welcome to our dedicated page for Corcept Therapeutics SEC filings (Ticker: CORT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Parsing Corcept Therapeutics’ SEC documents can feel like decoding a clinical protocol. The company’s filings overflow with data on glucocorticoid receptor trials, hypercortisolism patient outcomes, and R&D spend that shifts with every Phase 3 update—details investors can’t ignore yet rarely have time to dissect. Stock Titan’s AI turns these dense pages into clear takeaways, so “Corcept Therapeutics SEC filings explained simply” is more than a promise; it’s a deliverable.
Need the latest “Corcept Therapeutics quarterly earnings report 10-Q filing” or want to see how rising trial costs flow through cash burn? Our platform captures each 10-Q the moment it posts to EDGAR, then highlights revenue from Korlym, pipeline expense, and guidance shifts. The full annual report—think “Corcept Therapeutics annual report 10-K simplified”—is automatically condensed, surfacing FDA risk factors and licensing obligations in minutes. Prefer narrative? The earnings report filing analysis module answers searches like “Corcept Therapeutics earnings report filing analysis.” Sudden study read-outs? An “Corcept Therapeutics 8-K material events explained” panel pinpoints what changed and why. All of this exemplifies understanding Corcept Therapeutics SEC documents with AI.
Monitoring management sentiment? Real-time dashboards surface every “Corcept Therapeutics insider trading Form 4 transactions.” You’ll also find the exact phrase “Corcept Therapeutics Form 4 insider transactions real-time” already filtered by officer, option exercise, and date. Proxy statements reveal leadership incentives for anyone researching “Corcept Therapeutics proxy statement executive compensation.” Whether you’re tracking catalysts, benchmarking R&D efficiency, or following “Corcept Therapeutics executive stock transactions Form 4,” our AI-powered summaries, smart search, and export tools put the entire universe of Corcept Therapeutics filings within easy reach.
On 08/05/2025, Corcept Therapeutics (CORT) Chief Development Officer William Guyer filed a Form 4 detailing a tiny, Rule 10b5-1-planned transaction. He exercised 14 stock options at an exercise price of $21.65 (code M) and immediately sold the same 14 common shares at $71.77 (code S). After the trades, Guyer directly holds 5,487 common shares and still owns 385,007 unexercised options expiring 09/01/2031.
The gross sale proceeds are roughly $1,000, an amount immaterial relative to Corcept’s market cap and Guyer’s remaining equity stake. No other insider activity or company developments are disclosed. Given the de-minimis size and pre-arranged nature, the filing is unlikely to influence investor sentiment or signal a change in management’s outlook.
Corcept Therapeutics (CORT) – Form 4 filing, 08/05/2025: Chief Accounting & Technology Officer Joseph Douglas Lyon exercised 5,823 employee stock options at an exercise price of $13.56 (cost ≈ $79k) and immediately sold the same 5,823 shares under a pre-arranged 10b5-1 plan at a weighted-average $67.5129, generating gross proceeds of ≈ $393k and a spread of ≈ $314k before taxes.
Following the transactions Lyon directly owns 10,066 CORT common shares, including 1,552 unvested RSAs that vest one year from their respective grant dates, and retains 31,571 vested options. No other classes of securities were affected. The transaction neither alters total shares outstanding nor signals corporate fundamentals, but it represents a partial monetisation by a senior officer at ~5× the option strike.
Corcept Therapeutics Inc. (CORT) filed a Form 144 indicating that William Guyer intends to sell up to 20,000 common shares through broker Stifel Nicolaus on or about 08/05/2025. The shares have an estimated aggregate market value of $1.44 million, based on recent market prices. Corcept has 106.04 million shares outstanding, so the planned sale represents roughly 0.02% of total shares.
The filing also discloses that Guyer has already sold 64,301 shares in the past three months, generating $4.73 million in gross proceeds across six transactions. The forthcoming sale continues this selling trend but remains immaterial in size relative to total float. No pricing, earnings, or operational data are provided in the notice, and the signer affirms no undisclosed adverse information.
Corcept Therapeutics Inc. (CORT) – Form 144 filing discloses a proposed sale of 5,000 common shares by shareholder Joseph D. Lyon. The shares will be routed through Stifel Nicolaus & Co. on the NASDAQ with an estimated aggregate market value of $335,850 (based on the indicated $67.17 reference price). The company has 106.04 million shares outstanding, so the planned sale represents roughly 0.005 % of total shares.
The filer reports additional sales over the past three months totaling 18,527 shares for gross proceeds of $1.37 million. When combined with the proposed sale, Lyon’s total disposition for the rolling three-month window would reach 23,527 shares (~0.022 % of shares outstanding).
No purchase price was deferred; the 5,000 shares were acquired via stock-option exercise on 08/01/2025 and will be sold for cash. The filing contains the standard representation that the seller is unaware of undisclosed material adverse information and does not reference a Rule 10b5-1 plan.
Given the small size relative to the public float and absence of additional corporate disclosures, the filing appears routine and is unlikely to have a material impact on CORT’s valuation or trading dynamics.
Corcept Therapeutics (CORT) – Form 144 filing. President Sean Maduck has filed to sell 20,000 common shares through broker Stifel Nicolaus on or about 01 Aug 2025. At the 07/31/25 reference price, the sale is valued at $1.34 million. The shares were just acquired the same day via stock-option exercise; therefore the transaction is likely part of routine option monetisation.
Maduck has already disposed of 64,403 shares during the past three months for ~$4.79 million in gross proceeds. After the proposed trade, cumulative sales disclosed in the filing period reach ~84 k shares. CORT has 106.04 million shares outstanding, making the new sale ~0.02 % of outstanding stock and therefore not materially dilutive. No earnings, guidance or operational data are provided; this notice is strictly an insider-sale disclosure.
Corcept Therapeutics (CORT) – Form 4 insider activity
Sean Maduck, President of Corcept Endocrinology, exercised low-priced options and immediately sold the underlying shares pursuant to a 10b5-1 plan:
- 17 Jul 2025: Exercised 4,315 options at $5.05; sold 4,315 shares at a weighted-avg $73.4771.
- 18 Jul 2025: Exercised 473 options at $5.05; sold 473 shares at $73.4404.
Total shares sold: 4,788; gross proceeds ≈ $351k; per-share spread ≈ $68.4.
Post-trade holdings: 17,705 shares direct; 99,693 shares indirect (89,693 trust + 10,000 LLC); 56,993 vested options; 1,877 unvested RSAs.
The divestiture equals ~4 % of Maduck’s reported equity exposure and was pre-scheduled, suggesting limited informational content for the broader CORT investment thesis.
FAQ
What is the current stock price of Corcept Therapeutics (CORT)?
What is the market cap of Corcept Therapeutics (CORT)?
